Diagnosis of focal nodular hyperplasia with MRI: Multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium

American Journal of Roentgenology

Volumn 199, Issue 1, 2012, Pages 35-43

  Gupta, Rajan T ^a   Iseman, Christine M ^b   Leyendecker, John R ^c   Shyknevsky, Inna ^b   Merkle, Elmar M ^a   Taouli, Bachir ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Focal nodular hyperplasia; Gadobenate dimeglumine; Gadoxetate disodium; Liver; MRI

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOXETIC ACID;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; FEMALE; HEPATOBILIARY SYSTEM; HUMAN; LIVER FOCAL NODULAR HYPERPLASIA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; CONTRAST MEDIA; FEMALE; FOCAL NODULAR HYPERPLASIA; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84863640521     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.11.7757     Document Type: Article

References (29)

1. Reimer P, Schneider G, Schima W. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 2004; 14:559-578 (Pubitemid 38444568)
2. Ba-Ssalamah A, Uffmann M, Saini S, Bastati N, Herold C, Schima W. Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions. Eur Radiol 2009; 19:342-357
3. Ringe KI, Husarik DB, Sirlin CB, Merkle EM. Gadoxetate disodium-enhanced MRI of the liver. Part 1. Protocol optimization and lesion appearance in the noncirrhotic liver. AJR 2010; 195:13-28
4. Cruite I, Schroeder M, Merkle EM, Sirlin CB. Gadoxetate disodium-enhanced MRI of the liver. Part 2. Protocol optimization and lesion appearance in the cirrhotic liver. AJR 2010; 195:29-41
5. Seale MK, Catalano OA, Saini S, Hahn PF, Sahani DV. Hepatobiliary- specific MR contrast agents: role in imaging the liver and biliary tree. RadioGraphics 2009; 29:1725-1748
6. Vogl TJ, Kummel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996; 200:59-67 (Pubitemid 26197732)
7. Dahlström N, Persson A, Albiin N, Smedby O, Brismar TB. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd- EOB-DTPA in healthy subjects. Acta Radiol 2007; 48:362-368 (Pubitemid 46633865)
8. Grazioli L, Morana G, Federle MP, et al. Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine. Radiology 2001; 221:731-739 (Pubitemid 33101765)
9. Grazioli L, Morana G, Kirchin MA, Schneider G. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005; 236:166-177 (Pubitemid 40853309)
10. Zech CJ, Grazioli L, Breuer J, Reiser MF, Schoenberg SO. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol 2008; 43:504-511
11. Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995; 195:785-792
12. Petersein J, Spinazzi A, Giovagnoni A, et al. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging - a multicenter phase III clinical study. Radiology 2000; 215:727-736 (Pubitemid 30346007)
13. Carlos RC, Hussain HK, Song JH, Francis IR. Gadolinium-ethoxybenzyl- diethylenetriamine pentaacetic acid as an intrabiliary contrast agent: preliminary assessment. AJR 2002; 179:87-92 (Pubitemid 34694816)
14. Brismar TB, Dahlstrom N, Edsborg N, Persson A, Smedby O, Albiin N. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers. Acta Radiol 2009; 50:709-715
15. Feuerlein S, Gupta RT, Boll DT, Merkle EM. Hepatocellular MR contrast agents: enhancement characteristics of liver parenchyma and portal vein after administration of gadoxetic acid in comparison to gadobenate dimeglumine. Eur J Radiol [Epub 2011 Jun 28]
16. Lee MS, Lee JY, Kim SH, et al. Gadoxetic acid disodium-enhanced magnetic resonance imaging for biliary and vascular evaluations in preoperative living liver donors: comparison with gadobenate dimeglumine-enhanced MRI. J Magn Reson Imaging 2011; 33:149-159
17. Filippone A, Blakeborough A, Breuer J, et al. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine. J Magn Reson Imaging 2010; 31:356-364
18. Frydrychowicz A, Nagle SK, D'Souza SL, Vigen KK, Reeder SB. Optimized high-resolution contrast-enhanced hepatobiliary imaging at 3 tesla: a cross-over comparison of gadobenate dimeglumine and gadoxetic acid. J Magn Reson Imaging [Epub 2011 Jul 12]
19. Cornfeld DM, Israel G, McCarthy SM, Weinreb JC. Pelvic imaging using a T1W fat-suppressed three-dimensional dual echo Dixon technique at 3T. J Magn Reson Imaging 2008; 28:121-127 (Pubitemid 351956474)
20. Rosenkrantz AB, Neil J, Kong X, et al. Prostate cancer: comparison of 3D T2-weighted with conventional 2D T2-weighted imaging for image quality and tumor detection. AJR 2010; 194:446-452
21. Vogl TJ, Pegios W, McMahon C, et al. Gadobenate dimeglumine: a new contrast agent for MR imaging-preliminary evaluation in healthy volunteers. AJR 1992; 158:887-892
22. Schneider G, Maas R, Schultze Kool L, et al. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol 2003; 38:85-94 (Pubitemid 36125892)
23. Bashir MR, Merkle EM. Improved liver lesion conspicuity by increasing the flip angle during hepatocyte phase MR imaging. Eur Radiol 2011; 21:291-294
24. Bashir MR, Husarik DB, Ziemlewicz TJ, Gupta RT, Boll DT, Merkle EM. Liver MRI in the hepatocyte phase with gadolinium-EOB-DTPA: does increasing the flip angle improve conspicuity and detection rate of hypointense lesions? J Magn Reson Imaging 2012; 35:611-616
25. Haradome H, Grazioli L, Al Manea K, et al. Gadoxetic acid disodium-enhanced hepatocyte phase MRI: can increasing the flip angle improve focal liver lesion detection? J Magn Reson Imaging 2012; 35:132-139
26. Wanless IR, Mawdsley C, Adams R. On the pathogenesis of focal nodular hyperplasia of the liver. Hepatology 1985; 5:1194-1200 (Pubitemid 16222291)
27. Reddy KR, Kligerman S, Levi J, et al. Benign and solid tumors of the liver: relationship to sex, age, size of tumors, and outcome. Am Surg 2001; 67:173-178 (Pubitemid 33738212)
28. Becker YT, Raiford DS, Webb L, Wright JK, Chapman WC, Pinson CW. Rupture and hemorrhage of hepatic focal nodular hyperplasia. Am Surg 1995; 61:210-214
29. Sun HY, Lee JM, Shin C, et al. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or = 2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol 2010; 45:96-103